nilutamide has been researched along with Osteoporosis in 2 studies
Osteoporosis: Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Osteoporosis is a common disease in which the risk of fracture increases due to decreased bone mass and qualitative skeletal changes." | 2.82 | Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998-2021). ( Bian, J; Chen, R; Li, M; Li, Z; Tang, J; Tian, Y; Xie, Y; Xu, X; Zhang, Y; Zhang, Z, 2022) |
| "Osteoporosis was documented in at least one site evaluated in 41 patients (37%)." | 2.71 | Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study. ( Crook, J; Dahrouge, S; Malone, S; Perry, G; Segal, R, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xie, Y | 1 |
| Tian, Y | 1 |
| Zhang, Y | 1 |
| Zhang, Z | 1 |
| Chen, R | 1 |
| Li, M | 1 |
| Tang, J | 1 |
| Bian, J | 1 |
| Li, Z | 1 |
| Xu, X | 1 |
| Malone, S | 1 |
| Perry, G | 1 |
| Segal, R | 1 |
| Dahrouge, S | 1 |
| Crook, J | 1 |
1 review available for nilutamide and Osteoporosis
| Article | Year |
|---|---|
Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998-2021).
Topics: Androgen Antagonists; Androgens; Humans; Osteoporosis; Receptors, Androgen; Structure-Activity Relat | 2022 |
1 trial available for nilutamide and Osteoporosis
| Article | Year |
|---|---|
Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Disease-Free Survival; Follow- | 2005 |